newsfilter
← Latest News
PR Newswire·

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

  • BioArctic AB has entered a research & collaboration agreement with Eli Lilly to combine BioArctic's BrainTransporter technology with an undisclosed Lilly drug candidate for neurodegeneration.
  • BioArctic will receive a USD 30 million upfront payment & is eligible for up to USD 770 million in milestone payments.
  • BioArctic will earn tiered mid-single digit royalties on future global product sales if the therapy reaches the market.
  • BioArctic will develop the new drug candidate, while Lilly assumes full responsibility for global development & commercialization.
  • This marks BioArctic's fourth collaboration utilizing BrainTransporter technology, with the company retaining rights for other therapy areas.
  • The BrainTransporter technology facilitates drug passage across the blood-brain barrier via the transferrin receptor to improve efficacy & safety.
  • BioArctic is a Swedish biopharma company known for co-inventing Leqembi® with Eisai & developing treatments for Alzheimer's, Parkinson's, & ALS.